Rather than conducting pre-market assessment, the TGA assures the safety of listed complementary medicines through a program of random and targeted post-marketing reviews. Post-market reviews ensure that listed complementary medicines comply with applicable regulatory standards and requirements, including manufacturing in accordance with Good Manufacturing Practice (GMP). Where a post-market review identifies compliance issues, the complementary medicine may be cancelled from the Australian register of therapeutic goods (ARTG).
The TGA currently uses random selections and information from external sources (for example, suspected adverse reactions and market place surveillance) to identify listed complementary medicines for post-market review.